Kodiak Sciences to Present at American Chemical Society Fall 2025

Rhea-AI Summary

Kodiak Sciences (NASDAQ:KOD), a precommercial retina-focused biotech company, will present its glaucoma pipeline programs at the American Chemical Society Fall 2025 Meeting on August 19, 2025, in Washington, D.C.

The company is developing dual-mechanism therapies using its Antibody Biopolymer Conjugate Drug (ABCD) platform. The treatment combines a NLRP3 inhibitor targeting neuroinflammation with an IOP-lowering agent, delivered via quarterly intravitreal injection. Additionally, Kodiak is advancing its VETi™ program, an AI-enabled wearable headset designed to improve clinical trial testing efficiency and accuracy.

PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's pipeline programs in glaucoma at the American Chemical Society (ACS) Fall 2025 Meeting on Tuesday, August 19, 2025, in Washington, D.C.

Glaucoma is the leading cause of irreversible blindness, affecting approximately 76 million people worldwide. While currently approved eye drops effectively lower intraocular pressure (IOP) –the only modifiable risk factor– there are no approved therapies directly targeting the underlying optic neuropathy. Developing neuroprotective treatments remains challenging due to limitations in regulatory endpoints, constraints in trial design, and drug delivery barriers for small molecules targeting retinal ganglion cells.

"At Kodiak Sciences, we are advancing dual-mechanism therapies designed to address the two key drivers of glaucoma optic neuropathy," said Dolly S. Chang, MD, PhD, Chief Scientific Officer at Kodiak Sciences. "Leveraging our Antibody Biopolymer Conjugate Drug (ABCD) platform, we combine a novel small-molecule NLRP3 inhibitor –targeting neuroinflammation and optic nerve damage– with an IOP-lowering agent, both delivered in a single intravitreal injection designed for quarterly dosing. This dual-acting approach aims to provide a disease-modifying treatment for glaucoma optic neuropathy in a durable pharmacologic package."

Beyond therapeutics, Kodiak is innovating in clinical trial design to accelerate drug development through digital health technologies. The VETi™ (Visual Engagement Technology and Imager) program has made significant advancements in hardware, software, and algorithm development. VETi is an AI- and machine learning-enabled wearable headset with the potential to increase testing frequency and accuracy, reduce variability, and ultimately enable new clinically meaningful endpoints.

Presentation details are below:

Title: Unmet clinical endpoints and therapeutics for retinal diseases: Challenges and innovations

Presenter: Dolly S. Chang, M.D., Ph.D., Chief Scientific Officer, Kodiak Sciences Inc.

Date and time: August 19^th, 2025 2:35 PM – 3:05 PM EDT. This presentation is part of the symposium titled "EyeNovation: Small Molecule Drug Discovery for Common Ocular Diseases" scheduled from 2:00 pm - 5:15 pm EDT.

Slides of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. 

Kodiak^®, Kodiak Sciences^®, ABC^®, ABC Platform^®, ABCD^™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

About ABCD^™ Platform

Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("API's") into Kodiak's proprietary biopolymer backbone to enable multi-mechanism and high drug-antibody-ratio ("DAR") medicines. The diverse API's are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways. The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial diseases and builds directly from our Antibody Biopolymer Conjugate technology and its 15 years of design, development and manufacturing experience. We call this platform extension our Antibody Biopolymer Conjugate Drug ("ABCD") Platform because we are extending our platform capabilities to include the conjugation of small molecule drugs and other API's whereas historically, we primarily conjugated biologics such as antibodies. 

For more information, please visit www.kodiak.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: leveraging our ABCD platform to develop a disease-modifying therapy that targets neuroinflammation and optic nerve damage; the unique combination of high DAR and tailored therapeutic benefit offering the potential for broad application to multifactorial diseases; our platform's capabilities to include the conjugation of small molecule drugs and other APIs; and the advancement and potential of the VETi program. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "could," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. For a discussion of risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.

View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-american-chemical-society-fall-2025-302533816.html

SOURCE Kodiak Sciences Inc.

FAQ

When is Kodiak Sciences (KOD) presenting at the ACS Fall 2025 Meeting?

Kodiak Sciences will present on August 19, 2025, from 2:35 PM to 3:05 PM EDT in Washington, D.C.

What is Kodiak Sciences developing for glaucoma treatment?

Kodiak is developing dual-mechanism therapies that combine a NLRP3 inhibitor for neuroinflammation with an IOP-lowering agent, delivered through quarterly intravitreal injections.

What is Kodiak Sciences' VETi™ program?

VETi™ is an AI- and machine learning-enabled wearable headset designed to increase testing frequency and accuracy, reduce variability, and enable new clinical endpoints.

Where can investors access Kodiak Sciences' ACS presentation slides?

The presentation slides will be available in the 'Events and Presentations' section of Kodiak's website at http://ir.kodiak.com/.